Company intelligence / Profile preview
Lumen Bioscience
Seattle, Washington, USAlumen.bio ↗
- Ownership
- Private
- Employees
- ~90
- Development stage
- Other
01
Overview
Lead program LMN-801 for weight loss is in development, with several earlier-stage metabolic programs. LMN-201 for C. difficile infection prevention was the first rationally engineered, complex biologic cocktail to enter human clinical trials.
- Therapeutic areas
- GastroenterologyMetabolic DisordersInfectious Diseases
- Modalities
- Biologic drugstherapeutic proteinsantibodiescytokinesenzyme cocktails
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
BARDACARBXThe Bill & Melinda Gates FoundationUSAMRD/MTEC
04
Financials
- Market cap
- $21.3M
- Total revenue
- $79.2M
- Enterprise value
- $893.8M
Beyond the preview
Go deeper on Lumen Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lumen Bioscience.